Faculty Profiles - MASUYAMA Hisashi

Papers - MASUYAMA Hisashi

Division display 361 - 380 of about 762 ／ All the affair displays >>

Kidney cyst infection through a fistula between bladder and retroperitoneal abscess in a polycystic kidney disease patient. International journal

Takato Nakadoi, Kenji Tsuji, Takehiro Iwata, Eriko Eto, Hisashi Masuyama, Koji Tomita, Takao Hiraki, Shinji Kitamura, Hitoshi Sugiyama, Jun Wada

Nephrology (Carlton, Vic.) 27 ( 4 ) 383 - 384 2021.8

A randomized phase 3 trial evaluating antithrombin gamma treatment in Japanese patients with early-onset severe preeclampsia (KOUNO-TORI study): Study protocol. International journal

Shigeru Saito, Kenichi Takagi, Junji Moriya, Takao Kobayashi, Naohiro Kanayama, Hiroshi Sameshima, Mamoru Morikawa, Haruhiko Sago, Tomoko Adachi, Akihide Ohkuchi, Satoru Takeda, Hisashi Masuyama, Hiroyuki Seki

Contemporary clinical trials 107 106490 - 106490 2021.8

Language：English Publishing type：Research paper (scientific journal) Publisher：ELSEVIER SCIENCE INC

INTRODUCTION: Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. Several studies have demonstrated the beneficial effects of antithrombin replacement in patients with preeclampsia. Here, we describe the study protocol of KOUNO-TORI (KW-3357 randOmized, mUlti-center, double-bliNd, placebO-controlled phase 3 sTudy in patients with early Onset pReeclampsIa) to evaluate recombinant human antithrombin gamma (rhAT-gamma) for the treatment of early-onset severe de novo preeclampsia. MATERIAL AND METHODS: Patients with early-onset severe de novo preeclampsia who are ≥24 to <32 weeks pregnant at the time of registration and have an antithrombin activity of ≤100% at screening are included. The target population is selected based on a reanalysis of the data of a previous plasma-derived antithrombin phase 3 study. Primary endpoint is the prolongation of pregnancy from the initiation of rhAT-gamma treatment to the pregnancy termination. Secondary endpoints include gestational age in terms of achievement of 32- and 34-weeks'gestation, and gestational age in terms of achievement of 28 weeks' gestation for patients enrolled at <28 weeks' gestation. Maternal, fetal, and neonatal outcomes will be assessed. DISCUSSION: As we have selected a specifically defined target population based on reanalysis of data of a previous plasma-derived antithrombin phase 3 study, the results of our study are expected to provide efficacy and safety data concerning rhAT-gamma treatment in Japanese patients. This study could help identify an effective novel treatment for such patients with early-onset severe preeclampsia for whom appropriate treatment is unavailable.

DOI： 10.1016/j.cct.2021.106490

Clinical Course of 60 Cesarean Scar Pregnancies.

Takashi Mitsui, Sakurako Mishima, Kazumasa Tani, Jota Maki, Eriko Eto, Kei Hayata, Hisashi Masuyama

Acta medica Okayama 75 ( 4 ) 439 - 445 2021.8

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

Early diagnosis and therapy are important in a cesarean scar pregnancy (CSP), which can cause uterine rupture with resultant massive bleeding. However, there are some reports of CSPs continued to term. The optimal management of CSPs remains unclear; therefore, we investigated the clinical courses of CSPs diagnosed and treated at perinatal institutions in the Chugoku and Shikoku regions of Japan. We enrolled 60 women diag-nosed with CSP at 21 institutions from January 2006 to December 2015. Of the 60 women diagnosed with CSP, 57 were treated. Pregnancy was terminated in 48 women and continued in 9. Thirteen women underwent transabdominal hysterectomy; they experienced no postoperative complications or allogeneic blood transfu-sion. Nine women received therapies such as dilation and curettage, and 26 received non-surgical therapies such as methotrexate and topical administration of potassium chloride. Among 9 women who chose to con-tinue with their CSP, 7 successfully delivered newborns, 2 had uterine ruptures in the second trimester, and all women required transabdominal hysterectomy. Diagnosis and therapy in the first trimester of pregnancy are important in the management strategy of a CSP. When continuing a CSP, the risk of uterine rupture and trans-abdominal hysterectomy must be considered.

DOI： 10.18926/AMO/62395

The Spiral Trial: A multicenter, randomized, controlled trial of Spiral thread sutures versus conventional thread sutures to prevent thinning of uterine scars following elective cesarean section. International journal

Jota Maki, Hikari Nakatou, Kazumasa Tani, Eriko Eto, Kei Hayata, Dan Yamamoto, Kenji Kai, Takashi Tamada, Kazuyo Akamatsu, Kunihiro Kawanishi, Keiichiro Nakamura, Hisashi Masuyama

Contemporary clinical trials 107 106449 - 106449 2021.8

Language：English Publishing type：Research paper (scientific journal) Publisher：ELSEVIER SCIENCE INC

BACKGROUND: The aim of this randomized controlled trial (RCT) is to investigate whether Spiral-thread sutures are superior to conventional sutures (0-Vicryl) for preventing uterine scar thinning following elective cesarean section. METHODS: This multicenter, parallel-group RCT will be conducted in four hospitals across three medical regions in Japan to assess 200 women (≥20 years old) with singleton pregnancies who are scheduled to undergo cesarean sections. Eligible women will be randomly assigned (1:1 ratio) to receive either the conventional uterine suture continuous absorption thread, which is most commonly used in Japan, or the Spiral thread. The primary endpoint is the degree of scar thinning, measured by transvaginal ultrasonography 6-7 months postoperatively, to evaluate the position of the uterus (anterior or posterior tilt) and myometrial wound thickness. The degree of thinning will be compared between the groups, and four measurements (mm) of the thinning area, including caudal distance, depth of the depression, remaining thickness of the myometrium on the serous side of the most depressed area, and width of the depression, will be recorded in the sagittal view on transvaginal ultrasound. Secondary endpoints will include total operative time, suture application time (from birth to the end of uterine suturing), operative blood loss, number of additional Z-sutures or continuous sutures required to stop bleeding, maternal abnormality frequency (surgical complications and postoperative infections), surgeon's years of experience, and clinical interpretation of individual subscale scores. DISCUSSION: This study shall provide important evidence on the optimal suture for preventing hysterotomy wound thinning after the first cesarean section. TRIAL REGISTRATION: National Institute of Public Health, Japan: jRCT1062200001 (May 7, 2020; https://rctportal.niph.go.jp/en/detail?trial_id=jRCT1062200001) and Okayama University Certified Review Board: CRB6180001 (April 9, 2020, version 3.0).

DOI： 10.1016/j.cct.2021.106449

ヒト絨毛細胞の浸潤におけるPROKR2を介したEG-VEGFの役割(The role of EG-VEGF through PROKR2 in the invasion of human trophoblast cells)

Tani Kazumasa, Mitsui Takashi, Mishima Sakurako, Oohira Akiko, Maki Jota, Eto Eriko, Hayata Kei, Nakamura Keiichiro, Masuyama Hisashi

The Journal of Obstetrics and Gynaecology Research 47 ( 8 ) 2829 - 2829 2021.8

妊娠中の母体の除脂肪量変化は新生児の出生体重3500g以上の予測因子となり得る(Maternal change in fat free mass during pregnancy can be a predictor of newborn birth weight more than 3,500g)

Eto Eriko, Mishima Sakurako, Oohira Akiko, Tani Kazumasa, Maki Jota, Hayata Kei, Masuyama Hisashi

The Journal of Obstetrics and Gynaecology Research 47 ( 8 ) 2863 - 2863 2021.8

妊娠高血圧症候群の母体から生まれた児の3歳までの身体発育に関する調査子宮内発育遅延児の発育に影響を及ぼす因子の検討(A survey on physical development up to the third year of life in offspring born to mothers with hypertensive disorders of pregnancy: Examination of factors influencing the development of small-for-gestational-age offspring)

Mishima Sakurako, Mitsui Takashi, Tani Kazumasa, Oohira Akiko, Maki Jota, Eto Eriko, Hayata Kei, Narai Yoko, Honda Tetsurou, Kai Kenji, Tada Katsuhiko, Harada Takashi, Maeda Kazuhisa, Nagai Ryuhei, Shimoya Koichiro, Abe Emiko, Matsubara Yuko, Murata Susumu, Miyoshi Hiroshi, Masuyama Hisashi

The Journal of Obstetrics and Gynaecology Research 47 ( 8 ) 2866 - 2866 2021.8

院内死戦期帝王切開と院外死戦期帝王切開の最近の症例(Recent cases of in-hospital perimortem cesarean delivery and out-of-hospital perimortem cesarean delivery)

Hayata Kei, Mishima Sakurako, Oohira Akiko, Tani Kazumasa, Maki Jota, Eto Eriko, Masuyama Hisashi

The Journal of Obstetrics and Gynaecology Research 47 ( 8 ) 2920 - 2920 2021.8

【専攻医必携! 術中・術後トラブル対処法-予期せぬ合併症で慌てないために】産科編帝王切開術

増山寿, 早田桂

臨床婦人科産科 75 ( 7 ) 620 - 626 2021.7

Language：Japanese Publisher：(株)医学書院

＜文献概要＞●綿密な術前診察・検査にてリスク評価を行い,想定されるさまざまな状況に備えて対処法を熟知し,さらに次の手を考えておくことが重要である.●日頃から迅速,確実な手術手技を目指したトレーニングと周術期の評価および管理に習熟し,手術ごとに振り返り,考え,研鑽を積んでいくことが手術上達のコツである.

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01564&link_issn=&doc_id=20210706150003&doc_link_id=10.11477%2Fmf.1409210441&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1409210441&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Short-term prediction of preeclampsia using the sFlt-1/PlGF ratio: a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study. International journal

Akihide Ohkuchi, Shigeru Saito, Tatsuo Yamamoto, Hisanori Minakami, Hisashi Masuyama, Keiichi Kumasawa, Jun Yoshimatsu, Takeshi Nagamatsu, Angela Dietl, Sonja Grill, Martin Hund

Hypertension research : official journal of the Japanese Society of Hypertension 44 ( 7 ) 813 - 821 2021.7

Language：English Publishing type：Research paper (scientific journal) Publisher：SPRINGERNATURE

Two prospective multicenter studies demonstrated that a soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio cutoff of ≤38 can rule out preeclampsia within 1 week with a negative predictive value (NPV) of 99.3% (PROGNOSIS) and 98.6% (PROGNOSIS Asia). We report a subanalysis of the Japanese cohort from the PROGNOSIS Asia study. Pregnant women with suspected preeclampsia between gestational weeks 18 + 0 days and 36 + 6 days were enrolled at eight Japanese sites. Primary objectives: Assess the performance of the Elecsys® sFlt-1/PlGF ratio cutoff ≤38 to rule out preeclampsia within 1 week and of the cutoff >38 to rule in preeclampsia within 4 weeks. Key secondary objectives: Prediction of maternal and fetal adverse outcomes (MAOs/FAOs) and their relationship with duration of pregnancy. Of 192 women enrolled, 180 (93.8%)/175 (91.1%) were evaluable for primary/combined endpoint analyses. Overall preeclampsia prevalence was 13.3%. A sFlt-1/PlGF ratio of ≤38 provided an NPV of 100% (95% confidence interval [CI], 97.5-100) for ruling out preeclampsia within 1 week, and a ratio of >38 provided a positive predictive value of 32.4% (95% CI, 18.0-49.8) for ruling in preeclampsia within 4 weeks. The area under the curve for the prediction of preeclampsia/maternal/fetal adverse outcomes within 1 week was 94.2% (95% CI, 89.3-97.8). After adjusting for gestational age and final preeclampsia status, Cox regression indicated a 2.8-fold greater risk of imminent delivery for women with a sFlt-1/PlGF ratio >38 versus ≤38. This subanalysis of Japanese women with suspicion of preeclampsia showed high predictive value for a Elecsys sFlt-1/PlGF ratio cutoff of 38 for short-term prediction of preeclampsia.

DOI： 10.1038/s41440-021-00629-x

Economic evaluation of the sFlt-1/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study. International journal

Akihide Ohkuchi, Hisashi Masuyama, Tatsuo Yamamoto, Takashi Kikuchi, Naoko Taguchi, Cyrill Wolf, Shigeru Saito

Hypertension research : official journal of the Japanese Society of Hypertension 44 ( 7 ) 822 - 829 2021.7

Language：English Publishing type：Research paper (scientific journal) Publisher：SPRINGERNATURE

The PRediction of short-term Outcomes in preGNant wOmen with Suspected preeclampsIa Study (PROGNOSIS) Asia validated the use of the soluble fms-like tyrosine 1/placental growth factor (sFlt-1/PlGF) ratio cutoff value of ≤38 to rule out the occurrence of preeclampsia in the short term in Asian women. We assessed the economic impact of the introduction of the sFlt-1/PlGF ratio test for predicting preeclampsia in Japan using data from the Japanese cohort of PROGNOSIS Asia. The cost analysis was developed with estimates in either a no-test scenario, with clinical decisions based on standard diagnostic procedures alone, or a test scenario, in which the sFlt-1/PlGF ratio test was used in addition to standard diagnostic procedures. For both scenarios, rates of hospitalization and other test characteristics were obtained from the results for the Japanese cohort in PROGNOSIS Asia. The total cost per patient was the main outcome of this cost analysis model. Introduction of the sFlt-1/PlGF ratio test using a cutoff value of 38 resulted in a reduced hospitalization rate compared with the rate in the no-test scenario (14.4% versus 8.7%). The reduction in the rate of hospitalizations led to an estimated 16 373 JPY reduction in healthcare costs per patient. The sFlt-1/PlGF ratio test is likely to reduce the unnecessary hospitalization of women at low risk of developing preeclampsia in the short term while also identifying high-risk individuals requiring appropriate management. Reducing unnecessary hospitalizations would result in significant cost savings in the Japanese healthcare system.

DOI： 10.1038/s41440-021-00624-2

当科における子宮頸癌に対するがんパネル検査の現況

松岡敬典, 小川千加子, 岡本和浩, 依田尚之, 久保光太郎, 春間朋子, 中村圭一郎, 平沢晃, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 63回 337 - 337 2021.7